enGene Therapeutics ENGN
NASDAQ ENGN
$2.41 +0.13 (+5.70%)
At close: Nov 13, 2026 · 4:00 PM EST

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026)

Updated

enGene Therapeutics (ENGN) reported Long-Term Debt Issuances of $25 million for fiscal Q1 2026 (quarter ended Jan 31, 2026).

Analysis

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026) Analysis & Trends

For FY2024 (ended Oct 31, 2024), enGene Therapeutics posted Long-Term Debt Issuances of $22.5 million, down 40.8% from FY2023.

  • By fiscal year, Long-Term Debt Issuances came in at $38 million in FY2023 (+106.5%) and $18.4 million in FY2022.
  • The fiscal Q1 2026 figure ranks as the highest quarterly Long-Term Debt Issuances since fiscal Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn -
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 9.98 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 enGene Therapeutics 161.50 Mn -832.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2026 25.00 Mn
Jan 31, 2024 22.50 Mn
Jul 31, 2023 30.00 Mn
API Access

enGene Therapeutics Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=ENGN&period=max&api_key=YOUR_API_KEY